Drug Discovery World

FEBRUARY 28, 2024

Using a technique they’ve dubbed ‘cancer shredding’, the researchers at Gladstone Institutes, California, programmed CRISPR to zero-in on repeating DNA sequences present only in recurrent tumour cells – and then obliterate those cells by snipping away at them.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

PLOS: DNA Science

JANUARY 4, 2024

.” CRISPRs are short DNA sequences, peppered with repeats, that latch onto DNA-cutting enzymes, commandeering and directing them to snip certain parts of a chromosome. The microbes deploy them to dismantle the genetic material of infecting viruses, a little like an immune response.

FDA Approval 52

FDA Approval DNA Clinical Trials Therapies 52

Broad Institute

AUGUST 7, 2023

Related people Paul Blainey Nir Hacohen A signaling protein known as STING is a critical player in the human immune system, detecting signs of danger within cells and then activating a variety of defense mechanisms. Paper Cited Liu B, Carlson R, et al. Human STING is a proton channel. Online August 3, 2023. DOI :10.1126/science.adf8974.

Regulations 91

Regulations Engineering Clinical Trials DNA 91

The Pharma Data

MAY 15, 2023

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera Gilead Sciences, Inc. Executive Vice President, Research, Gilead Sciences. About Gilead Sciences Gilead Sciences, Inc. The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

Drug Target Review

APRIL 3, 2024

Everything started in school with an experiment on isolating DNA from bananas. Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences.

Science 105

Science Clinical Development DNA Treatment 105

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Immune Response Therapies Treatment 52

Drug Target Review

APRIL 26, 2023

Gene-editing methods allow researchers to modify DNA, resulting in alterations in physical characteristics such as eye colour and susceptibility to diseases. To achieve this, scientists utilise various technologies that function similarly to scissors, precisely cutting the DNA at a particular location.

RNA 98

RNA Medical Schools Engineering DNA 98

Drug Target Review

NOVEMBER 6, 2023

For example, combining IO agents with ADCs to mount a two-pronged attack against cancer by activating an anti-cancer immune response and directly killing cancer cells may drive stronger and more durable responses in the clinic. References Blood Cancer UK.

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

DrugBank

MAY 15, 2024

This method was more about serendipity than science. In the early 20th century, the discovery process was largely random , focused on cytotoxic agents that kill cells by disrupting key cellular functions like DNA replication. But as molecular biology has advanced, so too has our approach to finding new drugs.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Drug Target Review

JUNE 9, 2023

An antigen is a protein that can induce an immune response in the body. While tumour cells share a majority of their DNA with healthy cells, they also carry numerous unique mutations. This first T-cell therapy product targets a common shared neoantigen found in patients with solid tumours.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Target Review

SEPTEMBER 8, 2023

The study’s outcomes are also the fruit of a fruitful collaboration involving scientists from the RIKEN Center for Integrative Medical Sciences in Japan, alongside local research teams from UC San Diego and the Salk Institute. The cell’s nucleus, containing compacted DNA, is centrally positioned within the cell. .”

Regulations 98

Regulations Research DNA Immune Response 98

Drug Discovery World

JULY 31, 2023

Matt Hill , Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. Regardless of the type of disease targeted, at the core of biotherapy development is synthetic biology and the use of synthetic DNA to programme specific behaviours within living cells.

DNA 130

DNA Vaccine Therapies Production 130

Drug Discovery World

APRIL 14, 2023

Carolyn R Bertozzi, PhD – Outstanding Achievement in Chemistry in Cancer Research Bertozzi is the Baker Family Director of Sarafan ChEM-H, the Anne T and Robert M Bass Professor in the School of Humanities and Sciences, Professor of Chemistry and, by courtesy, of Chemical and Systems Biology and of Radiology at Stanford University.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

Drug Discovery World

APRIL 15, 2023

As such, Codagenix has previously demonstrated that CodaLytic, a codon-modified influenza virus, can kickstart the cancer immunity cycle at various steps in several mouse models with differing baseline immune contextures.

Virus 130

Virus Clinical Trials Trials Therapies 130

LifeSciVC

MARCH 1, 2023

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more recent times has been romanticized in movies like Field of Dreams , but the concept also holds true in many areas of science.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. Delivering the IFN-β gene into tumors caused cancer cell apoptosis and activated both innate and adaptive anti-tumor immune responses.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Broad Institute

JUNE 27, 2024

Science (2024) Related content New gene delivery vehicle shows promise for human brain gene therapy My Quest to Cure Prion Disease — Before It’s Too Late | Sonia Vallabh | TED Prion diseases lead to rapid neurodegeneration and death and are caused by misshapen versions of the prion protein in the brain. Online June 27, 2024.

Disease 142

Disease Therapies Engineering Clinical Trials 142

Drug Discovery World

SEPTEMBER 6, 2022

It’s no surprise that investors have wanted to gain a portion of what is an exciting and emerging field on science, one which offers many opportunities to treat a wide range of diseases. The Skills Demand Survey Report presents a lack of graduate life sciences apprenticeship programmes as a key barrier. But challenges remain.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

PLOS: DNA Science

MAY 16, 2024

These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. • offers clues to how the virus might change.

Virus 82

Virus DNA RNA Vaccine 82

LifeSciVC

JULY 1, 2024

One thread that has run throughout it has been my passion for science as a lens for looking at the world. In particular, I love connecting science to daily life. Pfizer’s recent campaign around “ Science Will Win ” similarly appealed to the ethos of the power of science to help humanity. Remember life’s Central Dogma.

Science 85

Science Immune Response Molecular Biology RNA 85

Broad Institute

OCTOBER 11, 2023

The drugs work by blocking a protein, PD-1 — which helps keep immune responses in check — and stimulating the immune system to attack tumors. The researchers soon partnered with Calico Life Sciences , which in collaboration with AbbVie , discovered drug candidates that block the PTPN2 protein.

Research 137

Research Immune Response Clinical Trials Cell Biology 137

Drug Discovery World

JULY 8, 2024

For decades, the life sciences community held the belief that RNA was merely the intermediary messenger (mRNA) between DNA and protein, a dogma that has been the foundation of biology.

RNA 147

RNA Small Molecule Vaccine FDA Approval 147

Broad Institute

AUGUST 11, 2022

The study appears in Science. Microbial armory In an earlier study, the researchers scanned data on the DNA sequences of hundreds of thousands of bacteria and archaea, which revealed several thousand genes harboring signatures of microbial defense. Each of these viral proteins activated a different STAND ATPase to protect the cell.

DNA 52

DNA Virus Immune Response Bioinformatics 52

PLOS: DNA Science

FEBRUARY 8, 2024

The molecular tools of CRISPR were borrowed and developed from the natural immune response of bacteria to viruses – bacteriophages – that infect them. DNA Science recently covered perfumes resurrected from extinct plants, but using older and less precise recombinant DNA technology. CRISPR Hubris?

Immune Response 76

Immune Response DNA Engineering Virus 76

Codon

APRIL 30, 2023

Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. Read more at Science. Science abstracts were pulled from five different medical journals and then fed into ChatGPT. kilobases” of DNA into a plant genome. (My

Vaccine 52

Vaccine Engineering DNA RNA 52

Codon

APRIL 30, 2023

Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. Read more at Science. Science abstracts were pulled from five different medical journals and then fed into ChatGPT. kilobases” of DNA into a plant genome. (My

Vaccine 52

Vaccine Engineering DNA RNA 52

The Pharma Data

NOVEMBER 29, 2020

Compared to placebo, participants vaccinated with three HB-101 doses had: a 48 percent reduction in CMV viremia (presence of CMV DNA in the blood); a 42 percent reduction in the use of antiviral therapy; and. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system.

Vaccine 52

Vaccine Clinical Trials Disease Therapies 52

Drug Discovery World

NOVEMBER 13, 2023

Enkelejda Miho, PhD, Professor, University of Applied Sciences and Arts Northwestern Switzerland, and Managing Director, aiNET, on: ‘The singular immune response to dengue and machine learning identification of antibodies in high-throughput sequences’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147

Drug Target Review

OCTOBER 4, 2023

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. Science 261 , 212–215 (1993).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Codon

JULY 27, 2023

From an article in Science : “After 6 months, the most promising varieties had their lignin content reduced by 49.1% in Science. Their cone cells, which are responsible for color vision, don’t work like normal. Transcription factors are proteins that bind to DNA and control gene expression. From Sulis D.B.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

From an article in Science : “After 6 months, the most promising varieties had their lignin content reduced by 49.1% in Science. Their cone cells, which are responsible for color vision, don’t work like normal. Transcription factors are proteins that bind to DNA and control gene expression. From Sulis D.B.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 121

Therapies Virus DNA Clinical Trials 121

Drug Target Review

JANUARY 9, 2024

Prior to the new study, the laboratories of Dr Michael Levin, Vannevar Bush Professor of Biology at Tufts University School of Arts & Sciences, and Dr Josh Bongard at the University of Vermont, created multicellular biological robots from frog embryo cells, named xenobots. This study was published in Advanced Science.

Laboratories 59

Laboratories Immune Response DNA Science 59

Drug Discovery World

MAY 30, 2023

By analysing the diverse cell populations of a tumour, it is possible to predict drug responsiveness and personalise a treatment strategy to minimise the outgrowth of resistant subpopulations. The post National Cancer Research Month: Celebrating drug discovery innovation appeared first on Drug Discovery World (DDW).

Research 130

Research Targeted Protein Degradation Drugs RNA 130

The Pharma Data

APRIL 7, 2023

Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. The Company’s focus is on some of the most challenging cancers.

Trials 40

Trials DNA Treatment Therapies 40

Drug Discovery World

AUGUST 1, 2023

This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response. Another potential clinical pathway is to use engineered exogenous circRNAs to produce therapeutic proteins within target cells.

RNA 130

RNA Vaccine Drugs Disease 130